JPMorgan Cuts Stryker Price Target to $340 From $350
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Viatris Commences Tender Offer to Acquire Pacira BioSciences
M impact | EQUITY | Oct 30, 2026, 01:03 PM UTC
Alphabet Shares Fall 12.6%, Erasing About $482 Billion in Market Value
Alphabet shares fell 12.6% Thursday, their steepest one-day decline since the company’s 2004 public debut. The selloff erased about $482 billion in market value as investors focuse
H impact | EQUITY | Oct 30, 2026, 01:01 PM UTC
LyondellBasell Reports Higher Third-Quarter Revenue, Warns Middle East Recovery Will Be Slow
LyondellBasell reported higher quarterly revenue and said Middle East conditions will likely remain fluid. The body is truncated before details on a potential return to pre-conflic
M impact | EQUITY | Oct 30, 2026, 12:59 PM UTC
JPMorgan Downgrades Coursera to Neutral, Cuts Target to $5
JPMorgan lowered its price target from $8 to $5. The new target implies 7.3% upside from Coursera’s Oct. 29 close of $4.66.
M impact | EQUITY | Oct 30, 2026, 12:56 PM UTC
BofA Downgrades Intel to Neutral, Cuts Price Target to $100
BofA lowered its rating on Intel from Buy to Neutral and reduced its price target from $145 to $100.
M impact | EQUITY | Oct 30, 2026, 12:33 PM UTC
Regeneron Shares Rise More Than 8% Premarket After Q3 Earnings Beat
Regeneron reported stronger-than-expected third-quarter earnings, supported by demand for its eye treatments and higher collaboration revenue from Sanofi. Shares gained more than 8
M impact | EQUITY | Oct 30, 2026, 12:31 PM UTC